Taysha Gene Therapies (TSHA) Enterprise Value (2020 - 2026)

Taysha Gene Therapies has disclosed Enterprise Value across 7 years of filings, most recently posting -$277.0 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$277.0 million, down 136.69% year-over-year; the trailing twelve-month figure through Mar 2026 was -$277.0 million (down 136.69% YoY), and the FY2025 annual result was -$320.2 million, down 130.79% from the prior year.
• Enterprise Value came in at -$277.0 million for Q1 2026 at Taysha Gene Therapies, up from -$320.2 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$34.3 million in Q3 2022 to a low of -$320.2 million in Q4 2025.
• The 5-year median for Enterprise Value is -$140.8 million (2023), against an average of -$158.6 million.
• Across the five-year window, Enterprise Value surged 81.83% in 2022 and sank 378.86% in 2023, its largest moves.
• Taysha Gene Therapies' Enterprise Value stood at -$34.3 million in 2022, then sank by 316.4% to -$142.8 million in 2023, then gained by 2.87% to -$138.7 million in 2024, then sank by 130.79% to -$320.2 million in 2025, then increased by 13.49% to -$277.0 million in 2026.
• The last three Enterprise Value figures came in at -$277.0 million (Q1 2026), -$320.2 million (Q4 2025), and -$297.8 million (Q3 2025), per Business Quant data.